0000885725-22-000030.txt : 20221121 0000885725-22-000030.hdr.sgml : 20221121 20221121163222 ACCESSION NUMBER: 0000885725-22-000030 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20221118 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221121 DATE AS OF CHANGE: 20221121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 221406189 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 8-K 1 bsx-20221118.htm 8-K bsx-20221118
0000885725false00008857252022-11-182022-11-180000885725us-gaap:CommonStockMember2022-11-182022-11-180000885725bsx:SeniorNotedue2027Member2022-11-182022-11-180000885725bsx:A550MCPSSeriesAMember2022-11-182022-11-18


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________________

FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
_____________________________________________________________________

Date of Report (Date of earliest event reported): (November 21, 2022) November 18, 2022
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware1-1108304-2695240
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)

    300 Boston Scientific Way, Marlborough, Massachusetts                 01752-1234
    (Address of principal executive offices)                           (Zip Code)

(508) 683-4000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.01 par value per shareBSXNew York Stock Exchange
0.625% Senior Notes due 2027BSX27New York Stock Exchange
5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per shareBSX PR ANew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company   
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   



Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(i)2023 Annual Bonus Plan

On November 18, 2022, upon the recommendation of the Executive Compensation and Human Resources Committee (the “Compensation Committee”), the Board of Directors (the “Board”) of Boston Scientific Corporation (the “Company”) approved the Company’s 2023 Annual Bonus Plan effective for the performance period January 1, 2023 through December 31, 2023.

As part of the Company’s overall compensation program, the 2023 Annual Bonus Plan provides an annual cash incentive opportunity for eligible exempt and nonexempt indirect labor or equivalent personnel (including the Company’s named executive officers meeting the eligibility criteria) based on the achievement of certain performance metrics. The 2023 Annual Bonus Plan provides:

for a single bonus pool (the “Total Annual Bonus”) that will be based on the Company’s performance measured against achievement of corporate-level performance goals for adjusted earnings per share; global sales, as defined by the annual bonus plan, at constant currency rates and excluding the impact of acquisitions and divestitures not contemplated in the annual operating plan; environmental, social, and governance (ESG) Scorecard metrics; as well as a quality assessment;
a ceiling of 150% of the Aggregate Annual Target, with the Board having discretion to terminate, suspend or modify the plan and to reduce the Total Annual Bonus based on the Company’s performance relative to its quality objectives and performance of its quality systems;
an allocation of the Total Annual Bonus among corporate, global supply chain and each participating business, and region (each, a “participating unit”). For corporate and global supply chain funding units (other than manufacturing plants), funding will track to the Total Annual Bonus pool funding, within a range of 10% in either direction, depending on the CEO’s assessment of the participating unit’s performance. For businesses, regions, and manufacturing plants, funding will be based on each participating unit’s overall and relative performance measured against its achievement of that unit’s predetermined “Scorecard” performance metrics and goals and taking into consideration, as appropriate, other factors; such allocation will be a percentage of the annual bonus pool target for each participating unit (representing the total target annual bonuses of all eligible employees for the year within that unit) (each such allocated amount, an “Assigned Bonus Pool”); and
an allocation of the Assigned Bonus Pool for each participating unit among all managers of plan participants within that participating unit. Such managers will then evaluate the performance of the participants under their management and determine, for each participant, the percentage (between 0% and 150%) of the participant’s target annual bonus that will be used to determine the participant’s bonus award.
Awards to certain executive officers under the 2023 Annual Bonus Plan are subject to the Company’s recoupment policy, which provides that, to the extent permitted by law, the Company may seek reimbursement of a bonus award in the event of an executive officer’s misconduct or gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company. The Company may also seek reimbursement of a bonus award if there is a restatement of the Company’s financial results that would have reduced a previously granted bonus award’s size or payment. The amount to be recouped would be the amount of any such reduction. Finally, if the Company determines that it is required by law to apply a “clawback” or alternate recoupment provision to a bonus award, under the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”) or otherwise, then such clawback or recoupment provision also will apply to the bonus award, as applicable, as if it had been included on the date the 2023 Annual Bonus Plan was established.

This description of the 2023 Annual Bonus Plan does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of such plan. A copy of the 2023 Annual Bonus Plan is included in this filing as Exhibit 10.1 and incorporated herein by reference.
(ii)2023 Performance Share Programs

On November 18, 2022, upon the recommendation of the Compensation Committee, the Board approved the adoption of two performance share programs, the Boston Scientific Corporation 2023 Relative Total Shareholder Return Performance Share



Program (the “2023 rTSR PSP”) and the Boston Scientific Corporation 2023 Organic Net Sales Growth Performance Share Program (the “2023 Organic Net Sales PSP”). The 2023 rTSR PSP is substantially similar to the 2022 Total Shareholder Return Performance Share Program, with a modified funding schedule. The historical free cash flow performance share program has been replaced with the 2023 Organic Net Sales PSP. These programs represent an important component of the overall mix of the Company’s long-term incentive program. Under both programs, if the relevant program criteria are met, performance share awards will be granted to the Company’s executive officers in the form of restricted stock units issued under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan, which was amended and restated effective as of October 1, 2020 and previously approved by the Company’s stockholders. Awards to certain executive officers under both programs are subject to the Company’s recoupment policy, which provides that, to the extent permitted by law, the Company may seek recovery of performance share units in the event of an executive officer’s misconduct or gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company. In addition, if the Company determines that it is required by law to apply a “clawback” or alternate recoupment provision to a performance share award, under the Dodd-Frank Act or otherwise, then such clawback or recoupment provision also will apply to the performance share award, as applicable, as if it had been included on the date the performance share award was granted.
(A)2023 Relative Total Shareholder Return Performance Share Program

The purpose of the 2023 rTSR PSP is to align the Company’s executive compensation program with the interests of stockholders and to reinforce the concept of pay for performance by comparing the Total Shareholder Return (“TSR”) of the Company’s common stock to the TSR of the other companies included in the S&P 500 Healthcare Index over a three-year period beginning on January 1, 2023 and ending on December 31, 2025 (the “Performance Period”). The number of performance shares awarded will be in a range of 0% to 200% of each participant’s target number of awards based on the Company’s TSR rank. Performance share awards will vest only upon satisfaction of both the performance criteria and the payment eligibility criteria set forth in the 2023 rTSR PSP, subject to certain exceptions in the event of a change of control or termination for retirement, death or disability.

This description of the 2023 rTSR PSP does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of such program. A copy of the 2023 rTSR PSP is included in this filing as Exhibit 10.2 and incorporated herein by reference.

(B) 2023 Organic Net Sales Growth Performance Share Program

The purpose of the 2023 Organic Net Sales PSP is to align the Company’s executive compensation program with the interests of stockholders and to reinforce the concept of pay for performance by providing incentives for the achievement of key business performance objectives critical to the Company’s success. Under the 2023 Organic Net Sales PSP, performance will be measured by comparing the Company’s organic net sales growth, for the three-year period beginning on January 1, 2023 and ending on December 31, 2025 against its financial plan performance for organic net sales, as defined by the 2023 Organic Net Sales PSP. Organic net sales growth, as defined under the 2023 Organic Net Sales PSP, is net sales excluding the impact of foreign currency fluctuation and the impact of acquisitions and divestitures for which there are less than a full period of comparable net sales. The number of performance shares awarded will be in a range of 0% to 200% of each participant’s target number of awards, depending on such performance. Performance share awards will only vest upon satisfaction of both the performance criteria and the payment eligibility criteria set forth in the 2023 Organic Net Sales PSP, subject to certain exceptions in the event of a change of control or termination for retirement, death or disability.

This description of the 2023 Organic Net Sales PSP does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of such program. A copy of the 2023 Organic Net Sales PSP is included in this filing as Exhibit 10.3 and incorporated herein by reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d)  Exhibits





SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
                        
                                
Date:November 21, 2022BOSTON SCIENTIFIC CORPORATION
By:/s/ Susan Thompson
Susan Thompson
Vice President and Chief Corporate Counsel


EX-10.1 2 exhibit101bostonscientific.htm EX-10.1 Document
logo2021compensationplans.jpg

2023 Boston Scientific Annual Bonus Plan
Performance Period January 1 - December 31
Version: November 2022

I.    Establishment and Purpose of the Plan

Boston Scientific Corporation has established the Boston Scientific Corporation Annual Bonus Plan ("Plan"). As explained in detail below, the Plan basically works as follows. For each Performance Year, there is an Aggregate Bonus Pool, which is the sum of the bonus targets of all eligible participants. After the end of the Performance Year, the Committee determines the percentage of the pool that will be paid out as bonus for the year, based on the Company’s performance as to Global Sales, Adjusted Earnings Per Share, Environmental, Social, and Governance (ESG) Scorecard, and its attainment of quality goals. The percentage will be between 0% and 150%. The payable portion of the pool is then separated into an Assigned Bonus Pool for each Business Group, Region and Unit, based on their performance as to their respective Scorecards. The Compensation Management System then allocates the Assigned Bonus Pools among the managers, who evaluate the performance of the participants under their management and determine, for each participant, the percentage (between 0% and 150%) of the participant’s Target Annual Bonus that will be the participant’s Bonus Award for the Performance Year.

The Plan's purpose is to align the Company's interests and your interests as a Plan participant by providing incentive compensation for the achievement of Company and individual performance objectives.

The capitalized words and terms that are used throughout the Plan are defined in the Glossary in Article IX.

II.    Eligibility and Participation

You are eligible to participate in the Plan for a Performance Year if you satisfy all of the following eligibility criteria:

You are either a Regular Employee or an Eligible International Employee;

You are not eligible for commissions under any sales compensation plan of the Company (unless the written terms of the plan or program expressly permit participation in both that plan or program and the Plan);

You are not eligible to participate in any other incentive plan or program of the Company (unless the written terms of that plan or program expressly permit participation in both that plan or program and the Plan); and

You complete at least two full months of Eligible Service during the Performance Year.

For Exempt Employees and Eligible International Employees, if you are eligible to participate in the Plan for only part of the Performance Year (for example, because you change positions or business units during the Performance Year), then you may participate in the Plan on a prorated basis for the Performance Year, provided that you complete at least two full months of Eligible Service during the Performance Year. If you are eligible for prorated participation, the Bonus Award, if any, otherwise payable to you for the Performance Year will be prorated based on your percentage of time in an eligible position during the Performance Year. This paragraph does not apply to Non-Exempt Employees.





1

logo2021compensationplans.jpg

2023 Boston Scientific Annual Bonus Plan
Performance Period January 1 - December 31
Version: November 2022

III.    Target Annual Bonus

Exempt Employees and Eligible International Employees: For each Performance Year in which you are eligible to participate, you will be assigned a Target Annual Bonus, which will be a specified percentage of your annual base salary, determined based on your position. The Bonus Award, if any, that you ultimately receive for the Performance Year will be a percentage of your Target Annual Bonus, determined pursuant to Article IV. The Aggregate Bonus Pool for a Performance Year will be the sum of the Target Annual Bonuses of all employees who are eligible to participate in the Plan for the Performance Year. All Bonus Awards will be based on your annual base salary and incentive target as of December 31 of the Performance Year.

Non-exempt employees: For each Performance Year in which you are eligible to participate, you will be assigned a Target Annual Bonus, which will be a specified percentage of your total annual earnings including only regular pay, shift differentials and overtime earnings, determined based on your position. The Bonus Award, if any, that you ultimately receive for the Performance Year will be a percentage of your Target Annual Bonus, determined pursuant to Article IV. The Aggregate Bonus Pool for a Performance Year will be the sum of the Target Annual Bonuses of all employees who are eligible to participate in the Plan for the Performance Year. All Bonus Awards will be based on your annual earnings and incentive target as of December 31 of the Performance Year.

IV.    Steps For Determining Bonus Awards

Bonus Awards for a Performance Year will be determined pursuant to the following steps:

Step One: Establish performance goals, quality goals and the Corporate Performance Scale

On or before March 15 of a Performance Year, the Committee will establish performance goals for each of the Plan's Performance Metrics and quality goals for the Performance Year. The Performance Metrics are Global Sales, Adjusted Earnings Per Share and an ESG Scorecard. The Committee will also approve the Corporate Performance Scale for the Performance Year, which will be set forth in a separate schedule.
Step Two: Measure achievement and determine Total Annual Bonus

After the end of the Performance Year, the Committee will evaluate the Company's financial performance results for the Performance Year and determine the extent to which the performance goals were attained. The Committee will adopt a written resolution as to the extent of the attainment of the performance goals with respect to each of the Performance Metrics. Based on the extent to which the performance goals were attained, the Chief Executive Officer will make a recommendation to the Committee, consistent with the Corporate Performance Scale, as to the Applicable Percentage of the Aggregate Bonus Pool to be paid by the Company as the Total Annual Bonus for the Performance Year. Taking into account the Chief Executive Officer's recommendation and any other factors that the Committee, in its discretion, deems appropriate, the Committee will approve an Applicable Percentage for the Performance Year, which must be consistent with the Corporate Performance Scale. The Committee retains the right to reduce the Total Annual Bonus for the Performance Year based on the Committee's Quality Assessment.

Step Three: Allocate the Total Annual Bonus

The Chief Executive Officer will make a recommendation to the Committee as to how the Total Annual Bonus for the Performance Year should be allocated among the Business Groups and Regions, based on their overall and relative performance against their respective applicable
2

logo2021compensationplans.jpg

2023 Boston Scientific Annual Bonus Plan
Performance Period January 1 - December 31
Version: November 2022

Scorecards for the Performance Year. Taking into account the Chief Executive Officer's recommendation and any other factors that the Committee, in its discretion, deems appropriate, the Committee will approve an allocation of the Total Annual Bonus among the Business Groups and Regions for the Performance Year. The portion of the Total Annual Bonus allocated to a Business Group or Region (its Assigned Bonus Pool) will be a percentage of the total Target Annual Bonuses of all its employees who participate in the Plan for the Performance Year. If a Business Group or Region has Units, the leader of the Business Group or Region will divide the Assigned Bonus Pool among the Units, based on their overall and relative performance against each Unit's applicable Scorecard for the Performance Year, so that each Unit will then have its own Assigned Bonus Pool. A Business Group or Region that does not have Units (for example, Corporate) will have a single Assigned Bonus Pool.

Step Four: Determine participants' individual Bonus Awards

Once the Assigned Bonus Pool is determined for each Business Group, Region, or Unit, the amount of the Assigned Bonus Pool will be entered into the Compensation Management System, which allocates a portion of the Assigned Bonus Pool to each manager of Plan participants. Each manager will evaluate the performance of each participant under his or her management and enter into the Compensation Management System a rating percentage, from 0% to 150%, for each evaluated participant. The rating percentage that your manager assigns to you will, in turn, determine the percentage of your Target Annual Bonus that will be your Bonus Award for the Performance Year.

If participants leave the Company before the Payment Date and, as a result, do not earn their Bonus Awards for the Performance Year, their Bonus Awards will be reallocated by the Chief Executive Officer, in his or her discretion, to other participants who are employed on the Payment Date and will become part of the Bonus Awards paid to those other participants. As provided in Article V, all Bonus Awards for a Performance Year (including those reallocated pursuant to the previous sentence) will be paid to eligible participants no later than March 15 of the following year.

V.    Payment Conditions

Payment Date and Form of Payment. Bonus Awards in the United States will be made by March 15 of the year following the Performance Year for which the Bonus Awards are made. Bonus Awards outside the United States will be processed as soon as administratively possible in each region following the end of the Performance Year and after the Committee has adopted its written resolution as to the attainment of performance goals pursuant to Article IV. Your Bonus Award, if any, will be paid in a single lump sum payment.

Required Employment on the Payment Date. Except as otherwise expressly provided in this Article V, to be eligible to receive payment of any Bonus Award, you must be employed by the Company on the Payment Date for that Bonus Award. In other words, except as expressly provided in this Article V, if you cease employment with Boston Scientific Corporation and all of its Affiliates before the Payment Date, you will not be eligible to receive any Bonus Award that would otherwise have been payable to you if you had been a Company employee on that date. Conversely, if you are an employee of the Company on the Payment Date, you will be entitled to your Bonus Award, if any, even if you are not actively performing duties on that date. For example, if you are not required to report to work during a notification period applicable under a Company severance or separation plan, but you are still a Company employee during that period, and the Payment Date occurs during your notification period, you will remain eligible to receive your Bonus Award.


3

logo2021compensationplans.jpg

2023 Boston Scientific Annual Bonus Plan
Performance Period January 1 - December 31
Version: November 2022

Exception Under Written Company Plan or Agreement. If you are specifically exempted, under a written Company plan or agreement, from the requirement to be employed on the Payment Date, you may remain eligible for payment of your Bonus Award, depending on the terms of the applicable written plan or agreement. In such cases, the terms of such written plan or agreement will govern in all respects.
Layoff. Also notwithstanding any other provision of the Plan, if you are a participant and your employment ceases prior to the Payment Date by reason of Layoff, you may be eligible for payment of part or all of your Bonus Award, depending on the terms and conditions of the applicable severance pay plan, if any, for the country in which you are employed at the time of layoff. In the event that there is no country-specific severance plan for the country in which you are employed at the time of your Layoff, applicable law will apply. In the event a previously eligible participant is re-hired within the Performance Year after a layoff and meets the eligibility
criteria, if the participant was paid out a pro-rated bonus at the time of severance, then the payout period will not be bridged. If the re-hired participant did not receive a pro-rated bonus payout at the time of severance, then the payout period will be bridged, and participant will receive a pro-rated Bonus Award for the Performance Year.

Leaves of Absence. Also notwithstanding any other provision of the Plan, if you are a participant on a paid leave of absence, you are bonus eligible as long as you meet performance expectations during the Performance Year. Your Bonus Award will be made on the payment date within the applicable country. If you are a participant on an unpaid leave of absence, your Bonus Award, if any, will be pro-rated if the unpaid leave is longer than a continuous six (6) months in duration during the Performance Year. Country specific regulations regarding leaves of absence and bonus eligibility supersede this Plan document.

Retirement. Also notwithstanding any other provision of the Plan, if you are a participant for a Performance Year and your employment ceases due to Retirement prior to the Payment Date for a Bonus Award but after September 30 of the Performance Year to which the Bonus Award pertains, and you had at least nine months of Eligible Service in the Performance Year, you will be entitled to a prorated portion of the Bonus Award, if any, that would otherwise be paid you for the Performance Year. In such a case, proration will be based on the percentage of time in the Performance Year during which you were employed and eligible to participate in the Plan. The prorated Bonus Award, if any, will be paid on the Payment Date. For purposes of this paragraph, your employment ceases due to “Retirement” if, as of the date of your cessation of employment, (1) you had attained age 55, (2) you had accrued at least five years of service with the Company and (3) the sum of your age and years of service as of your date of cessation of employment equals or exceeds 65.

Death. For Exempt Employees and Eligible International Employees, if your employment ceases prior to the Payment Date by reason of your death, but you otherwise met all eligibility criteria specified in Article II, your estate may receive a prorated portion of the Bonus Award, if any, that would have been paid had you lived to the Payment Date. In such a case, proration will be based on the percentage of time in the Performance Year during which you were employed and eligible to participate in the Plan. The prorated Bonus Award, if any, will be paid on the Payment Date.
For Non-Exempt Employees, if your employment ceases prior to the Payment Date by reason of your death, but you otherwise met all eligibility criteria specified in Article II, your estate will receive your Bonus Award, if any, that would have been paid had you lived to the Payment Date.

Adjustment for Changes in Standard Hours. Also notwithstanding any other provision of the Plan, if you are an Exempt Employee or Eligible International Employee participant and have a change in standard hours (part-time to full-time, full-time to part-time) during a Performance Year, your Bonus Award, if any, for the Performance Year will be calculated as follows: Target Annual Bonus
4

logo2021compensationplans.jpg

2023 Boston Scientific Annual Bonus Plan
Performance Period January 1 - December 31
Version: November 2022

percentage multiplied by the average annualized base salary for each period of employment at a specific salary divided by the percentage of the year during which that salary was earned. For example, if your Target Annual Bonus percentage is 10% and you worked full-time for six (6) months at an annual base salary of 100,000 and moved to a part-time arrangement for the remaining (6) months at an annual base salary of 50,000, your bonus award, if any, would be 7,500. [0.10 x (100,000 x 0.50) = 5,000] and [0.10 x (50,000 x 0.50) = 2,500]. This paragraph does not apply to Non-Exempt Employee participants.

No Guarantee of a Bonus Award. Nothing in this Plan guarantees that any Bonus Award will be made to any individual. Receipt of a Bonus Award in one year does not guarantee eligibility in any future year.

VI.    Incentive Compensation Recoupment Policy

General Recoupment Policy. To the extent permitted by governing law, the Board, in its discretion, may seek reimbursement of a Bonus Award paid to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer. Further, in such case:

i.if you are a Current Executive Officer, the Board may seek reimbursement of all or a portion of the Bonus Award paid to you during the one-year period preceding the date on which such misconduct or dereliction of duty was discovered by the Company, or

ii.if you are a Former Executive Officer, the Board may seek reimbursement of all or a portion of the Bonus Award paid to you during the one-year period preceding the last date on which you were a Current Executive Officer.

Restatement of Financial Results. To the extent permitted by governing law, if you are an Executive Officer, the Board will seek reimbursement of a Bonus Award paid to you in the event of a restatement of the Company's financial results that reduced a previously granted Bonus Award's size or payment. In that event, the Board will seek to recover the amount of the Bonus Award paid to you that exceeded the amount that would have been paid based on the restated financial results.

Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a "clawback" or alternate recoupment provision to a Bonus Award, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to the Bonus Award, as applicable, as if it had been included on the date the Plan was established and the Company shall notify you of such additional provision.

VII.    Termination, Suspension or Modification and Interpretation of the Plan

The Board may terminate, suspend or modify (and if suspended, may reinstate with or without modification) all or part of the Plan at any time, with or without notice to participants. The Committee has sole authority over administration and interpretation of the Plan, and the Committee retains its right to exercise discretion as it sees fit.

The Committee reserves the exclusive right to determine eligibility to participate in this Plan and to interpret all applicable terms and conditions, including eligibility criteria, performance objectives

5

logo2021compensationplans.jpg

2023 Boston Scientific Annual Bonus Plan
Performance Period January 1 - December 31
Version: November 2022
and payment conditions, for the Company's executive officers. The Committee delegates to the Company’s highest human resources officer the authority to administer, and determine eligibility to participate in, the Plan and interpret all applicable terms and conditions for employees who are not executive officers of the Company. The determinations and interpretations of the Committee and its delegates will be conclusive.

All Bonus Awards are paid from the Company's general assets. No trust, account or other separate collection of amounts will be established for the payment of Bonus Awards under the Plan. Bonus Awards are unfunded obligations of the Company, so if and when a Bonus Award becomes due, a participant's rights to payment are no greater than the rights of a general unsecured creditor.

VIII.    Other

This document sets forth the terms of the Plan and is not intended to be a contract or employment agreement between you or any other participant and the Company. As applicable, it is understood that both you and the Company have the right to terminate your employment with the Company at any time, with or without cause and with or without notice, in acknowledgement of the fact that your employment relationship with the Company is “at will.”

IX.    Glossary

As used in the Plan, the following words and terms, when capitalized, have the following meanings:

Adjusted Earnings Per Share means, with respect to a Performance Year, Adjusted Net Income (loss) divided by weighted average shares outstanding for the Performance Year (determined in accordance with generally accepted accounting principles).

Adjusted Net Income (loss) equals the Company's GAAP Net Income (loss) excluding certain charges (credits) from GAAP net income, including, but not limited to, amortization expense, goodwill and intangible asset impairment charges, acquisition- and divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), certain investment impairment losses (gains), EU Medical Device Regulation implementation charges, pension termination charges, debt extinguishment charges and discrete tax items.

Affiliate means any corporation, trust, partnership, or any other entity that is considered to be a single employer with Boston Scientific Corporation under Code sections 414(b), (c), (m), or (o), such as a wholly-owned (or at least 80%-owned) subsidiary of Boston Scientific Corporation.

Aggregate Bonus Pool means, with respect to a Performance Year, the sum of the Target Annual Bonuses of all employees who are eligible to participate in the Plan for the Performance Year.

Applicable Percentage means, with respect to a Performance Year, a percentage, determined by the Committee in accordance with the Corporate Performance Scale, which is between 0% and no more than 150%. The Applicable Percentage is used to determine the portion of the Aggregate Bonus Pool that the Company will pay out as the Total Annual Bonus for the Performance Year.

Assigned Bonus Pool means, with respect to a Business Group, Region, or Unit for a Performance Year, the portion of the Total Annual Bonus assigned to the Business Group, Region, or Unit to be paid as Bonus Awards for the Performance Year to eligible participants who worked for the Business Group, Region, or Unit during the Performance Year.

6

logo2021compensationplans.jpg

2023 Boston Scientific Annual Bonus Plan
Performance Period January 1 - December 31
Version: November 2022

Board means the Board of Directors of Boston Scientific Corporation.

Bonus Award means, with respect to a participant for a Performance Year, the annual incentive bonus, if any, payable to the participant for the Performance Year, subject to the terms and conditions of the Plan.

Business Group means a functional or product-based area of the Company's business, as designated by the Chief Executive Officer from time to time.

Chief Executive Officer means the Chief Executive Officer of Boston Scientific Corporation.
Code means the Internal Revenue Code of 1986, as amended, and its interpretive rules and regulations.

Committee means the Executive Compensation and Human Resources Committee of the Board.
Company means Boston Scientific Corporation and its Affiliates.

Compensation Management System means the software tool used by the Company for various compensation management purposes.

Corporate Performance Scale means, with respect to a Performance Year, the schedule used to determine, based on the extent of attainment of the performance goals for the Performance Year, the Applicable Percentage of the Aggregate Bonus Pool to be paid as the Total Annual Bonus for the Performance Year. The Corporate Performance Scale must provide that the Applicable Percentage for a Performance Year cannot be less than 50%.

Current Executive Officer means any individual currently designated as an “officer” by the Board for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

Eligible International Employee means an international, international operations, or expatriate employee of the Company working in a position designated by the Company as eligible to participate in the Plan.

Eligible Service means periods in which you are considered, under the rules and procedures of the Company, to be in active service as a Regular Employee or Eligible International Employee (including, but not limited to, time away from work for approved vacation, recognized holidays, and FMLA leave).

Environmental, Social and Governance (ESG) Scorecard means, with respect to a Performance Year, performance against global gender and US (inclusive of Puerto Rico) multicultural goals, Engagement goals, and performance against annual environmental goals that are aligned with the Company’s environmental strat plan goals.

Executive Officer means any Current Executive Officer or Former Executive Officer.

Exempt Employee means an employee of the Company who is on the Company's United States payroll and (1) classified by the Company as a regular full-time or regular part-time Employee; (2) performs a job that the Company has determined to be exempt from the minimum wage and overtime requirements of the Fair Labor Standards Act of 1938, as amended (FLSA); and (3) is not any of the following:

classified by the Company as an intern, summer student, co-op employee, or similar short-term employee; or


7

logo2021compensationplans.jpg

2023 Boston Scientific Annual Bonus Plan
Performance Period January 1 - December 31
Version: November 2022

classified by the Company as a consultant, temporary or defined-term employee (such as temporary fellowship program employees), or similar category of limited-term employment, regardless of their work schedule or number of hours worked.

Former Executive Officer means any individual previously (but not currently) designated as an “officer” by the Board for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

Global Sales for purposes of the Annual Bonus Plan measures sales using constant currency rates and excludes acquisitions and divestitures not included in the annual operating plan.

Layoff means a layoff or similar involuntary termination from employment that renders you eligible for severance pay under a Company severance plan or applicable law.

Non-Exempt Employee means an employee of the Company who is on the Company's United States payroll and (1) classified by the Company as a regular full-time or regular part-time Employee; and (2) performs a job that the Company has determined to be non-exempt from the minimum wage and overtime requirements of the Fair Labor Standards Act of 1938, as amended (FLSA).

Payment Date means, with respect to a Performance Year, the date on which Bonus Awards for the Performance Year are paid to participants, which will be no later than March 15 of the following year.

Performance Metrics means Global Sales, Adjusted Earnings Per Share, and ESG Scorecard.

Performance Year for all metrics except environmental metrics, means the 12-month period beginning on January 1 and ending on the following December 31. For the environmental metrics, the 12-month period beginning October 1, 2022 and ending on the following September 30, 2023.

Plan means the Boston Scientific Annual Bonus Plan, which is set forth in this document, as it may be amended from time to time.

Quality Assessment means the process undertaken by the Committee following the end of each Performance Year, to evaluate the Company's progress made toward achievement of its quality objectives and the performance of the Company-wide quality system.

Region means a geographic region, as designated by the Chief Executive Officer from time to time, comprising a portion of the Company's international business.

Regular Employee means an employee of the Company who is on the Company's United States payroll and is considered an Exempt Employee or Non-Exempt Employee.

Retirement has the meaning given in Section V in the paragraph entitled “Retirement.”

Scorecard means, with respect to a Performance Year, the tool used to establish performance measures and objectives with respect to a Business Group, Region, or Unit for the Performance Year.

Target Annual Bonus has the meaning given to that term in Article III.

Total Annual Bonus represents, with respect to a Performance Year, the total dollars to be paid out by the Company to all participating employees as Bonus Awards for the Performance Year.

8

logo2021compensationplans.jpg

2023 Boston Scientific Annual Bonus Plan
Performance Period January 1 - December 31
Version: November 2022

Unit means a business unit of Business Group or Region, such as a plant or division (for a Business Group) or a country or group of countries (for a Region); the Units of a Business Group or Region may change from time to time.
9
EX-10.2 3 exhibit102bostonscientific.htm EX-10.2 Document
Boston Scientific Corporation (“Boston Scientific”)
Relative Total Shareholder Return Performance Share Program (“rTSR Program”)
Performance Period January 1, 2023 - December 31, 2025

I.Purpose of the rTSR Program

The purpose of the rTSR Program is to align Boston Scientific’s executive compensation program with the interests of shareholders and to reinforce the concept of pay for performance by comparing the Total Shareholder Return of shares of Boston Scientific Common Stock (the “Common Stock”) to the TSR of companies included in the S&P 500 Healthcare Index over a three-year period beginning on January 1, 2023.

The rTSR Program entails the grant of Restricted Stock Units, and the program shall be administered, under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “2011 LTIP”). Terms not defined in this rTSR Program document but defined in the 2011 LTIP shall have the same meaning as the 2011 LTIP.

II.     Eligible Participants

The rTSR Program covers members of the Executive Committee on the date that awards are granted under the rTSR Program as determined and in the amounts established by the Executive Compensation and Human Resources Committee of the Board of Directors (the “Committee”).

III. Performance Share Units

The Restricted Stock Units awarded under the rTSR Program (the “Performance Share Units”) shall vest only upon satisfaction of both the performance criteria described in this Section III and the payment eligibility criteria described in Section VII. The applicable performance criteria are based on the TSR of the Common Stock relative to the TSR of companies in the S&P 500 Healthcare Index.

The TSR for Boston Scientific and all other companies in the S&P 500 Healthcare Index will be measured over a three-year period beginning January 1, 2023 and ending on December 31, 2025 (the “Performance Period”).

The number of Performance Share Units as to which the performance criteria under this rTSR program shall be determined to have been satisfied will be in a range of 0% to 200% of the target number of Performance Share Units awarded to the participant as follows:

rTSR Performance
Percentile Rank
Performance Share Units as a Percent of Target
75th Percentile or above200%
55th Percentile100%
25th Percentile30%
Below 25th Percentile
0%

If the minimum level of performance is achieved, the number of Performance Share Units will be calculated linearly between each set of data points.

Following the end of the Performance Period, the Committee shall determine the number of Performance Share Units as to which the performance criteria of this program have been satisfied, which determination shall be final and binding. Shares of Common Stock will be delivered or otherwise made available to the participant no later than March 15, 2026 in


Boston Scientific Corporation (“Boston Scientific”)
Relative Total Shareholder Return Performance Share Program (“rTSR Program”)
Performance Period January 1, 2023 - December 31, 2025

settlement of the Performance Share Units as to which the performance criteria of this program have been satisfied if and to the extent the payment eligibility criteria of Section VII below are also satisfied. Any Performance Share Units as to which the performance criteria of this Section III have not been satisfied will be forfeited in their entirety.

IV.    Calculation of Total Shareholder Return and Definitions

The TSR for Boston Scientific and each other company in the S&P 500 Healthcare Index shall include any cash dividends paid during the Performance Period and shall be determined as follows:

Total Shareholder Return for the Performance Period =
(Change in Stock Price + Dividends Paid) / Beginning Stock Price

Beginning Stock Price” means the daily average closing price as quoted on the New York Stock Exchange or the NASDAQ Global Select Market, as applicable, of one (1) share of common stock for the two calendar months prior to the beginning of the Performance Period.

Change in Stock Price” means the difference between the Beginning Stock Price and the Ending Stock Price.

Dividends Paid” means the total of all cash dividends paid on one (1) share of stock during the Performance Period.

Ending Stock Price” means the daily average closing price as quoted on the New York Stock Exchange or the NASDAQ Global Select Market, as applicable, of one (1) share of common stock for the last two calendar months of the Performance Period.

Example: If the Beginning Stock Price for a company was $25.00 per share, and the company paid $2.50 in dividends over the Performance Period, and the Ending Stock Price was $30.00 per share (thereby making the Change in Stock Price $5.00 ($30.00 minus $25.00)), then the TSR for that company would be thirty percent (30%). The calculation is as follows: 0.30 = ($5.00 + $2.50) / $25.00

V.    Calculation of Percentile Performance

Following the calculation of the TSR for the Performance Period for Boston Scientific and each of the other companies in the S&P 500 Healthcare Index, Boston Scientific and the other companies in the S&P 500 Healthcare Index will be ranked, in order of maximum to minimum, according to their respective TSR for the Performance Period.

After this ranking, the percentile performance of Boston Scientific as compared to the other companies in the S&P 500 Healthcare Index shall be determined by the following formula:

percentileperformancecalcu.jpg
“P” represents the percentile performance which will be rounded, if necessary, to the nearest whole percentile by application of standard scientific rounding conventions.

“N” represents the number of companies in the S&P 500 Healthcare Index, including Boston Scientific.


Boston Scientific Corporation (“Boston Scientific”)
Relative Total Shareholder Return Performance Share Program (“rTSR Program”)
Performance Period January 1, 2023 - December 31, 2025


“R” represents Boston Scientific’s ranking versus the other companies in the S&P 500 Healthcare Index.

Example: If Boston Scientific ranked 10th out of 54 companies, the performance (“P”) therefore will be in the 83rd percentile.

This calculation is as follows: 0.83 = 1 – (10 – 1) / (54 – 1)

VI.     S&P 500 Healthcare Index

The companies currently included in the S&P 500 Healthcare Index can be found in Appendix A attached hereto.

Only companies in the S&P 500 Healthcare Index for an entire Performance Period will be used to determine the TSR percentile rank.

If two companies in the S&P 500 Healthcare Index merge, the surviving company shall remain in the S&P 500 Healthcare Index.

If a company in the S&P 500 Healthcare Index merges with, or is acquired by, a company that is not in the S&P 500 Healthcare Index, and the company in the S&P 500 Healthcare Index is the surviving company, then the surviving company shall be included in the S&P 500 Healthcare Index.

If a company in the S&P 500 Healthcare Index merges with, or is acquired by, a company that is not in the S&P 500 Healthcare Index, and the company in the S&P 500 Healthcare Index is not the surviving company or the surviving company is no longer publicly traded, then the surviving company shall not be included in the S&P 500 Healthcare Index.

Notwithstanding the foregoing, if a company in the S&P 500 Healthcare Index ceases to be listed in the Healthcare Sector under the Standard & Poor’s Global Industry Classification Standard (GICS) at any time during the Performance Period (including after a merger, acquisition or other business transaction described above), then it shall not be included in the S&P 500 Healthcare Index.

VII.    Payment Eligibility Criteria

Except as set forth below with respect to a Change in Control, no Performance Share Units shall vest prior to the end of the Performance Period (December 31, 2025).

If a participant’s employment with Boston Scientific and its Affiliates (the “Company”) terminates before the last day of the Performance Period, all of his or her Performance Share Units shall be forfeited in their entirety except as set forth below.

Participants on military, sick or other bona fide leave of absence on December 31, 2025 will not be deemed to have terminated employment with the Company if such absence does not exceed 180 days or, if longer, the period the participant retains the right by statute or by contract to return to employment with the Company.



Boston Scientific Corporation (“Boston Scientific”)
Relative Total Shareholder Return Performance Share Program (“rTSR Program”)
Performance Period January 1, 2023 - December 31, 2025

Subject to the terms of any separate Change in Control or similar agreement to which a participant is bound, if there is a Change in Control after December 31, 2023 but before the end of the Performance Period, shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this program have been satisfied using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2025, as determined by the Committee immediately prior to the consummation of the Change in Control. Such issuance shall occur within 70 days of the effective date of the Change in Control, on a prorated basis. The number of shares to be issued on a prorated basis shall be determined as follows: (# Performance Share Units achieved pursuant to the table in Section III * ((# of full and partial months during the Performance Period, rounded up to the nearest whole month/36)). The number of prorated shares to be issued to the participant, if any, will be approved by the Committee at its next regular meeting. In the event a Change in Control occurs prior to January 1, 2023, the Performance Share Units will be forfeited in their entirety.

If a participant’s employment with the Company terminates due to Retirement after December 31, 2023 but before the end of the Performance Period, the participant will continue to be eligible to vest in a prorated number of Performance Share Units and shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this program have been satisfied at the end of the Performance Period, but no later than March 15, 2026, on a prorated basis using the effective date of the participant’s termination of employment. The number of shares to be issued on a prorated basis shall be determined as follows: (# Performance Share Units achieved pursuant to the table in Section III * ((# of full and partial months worked during the Performance Period, rounded up to nearest whole month) / 36)). The number of prorated shares, if any, to be issued to the participant will be approved by the Committee at its regular meeting next following the date of the participant’s employment termination.

If a participant’s employment with the Company terminates due to death or Disability before the end of the Performance Period, the participant will continue to be eligible to vest in all of his or her Performance Share Units and shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this program have been satisfied at the end of the Performance Period, but no later than March 15, 2026. The number of shares, if any, to be issued to the participant will be approved by the Committee at its regular meeting next following the date of the participant’s employment termination.

VIII.     Termination, Suspension or Modification and Interpretation of the rTSR Program

The Committee has sole authority over administration and interpretation of the rTSR Program. The Committee hopes and expects to continue the program in effect but retains its right to exercise discretion as it sees fit, including to prospectively terminate, suspend or modify the rTSR program or criteria for eligible participation in future years. If suspended, the Committee may reinstate with or without modification all or part of the rTSR Program or criteria for eligible participation; However, no amendment of the Program after the grant date may materially and adversely impair a participant’s rights under awards made pursuant to the rTSR Program without the participant’s consent unless the amendment is necessary or desirable to facilitate compliance with applicable law, as determined in the sole discretion of the Committee. The Committee reserves the exclusive right to determine eligibility to participate in this rTSR Program and to interpret all applicable terms and conditions.



Boston Scientific Corporation (“Boston Scientific”)
Relative Total Shareholder Return Performance Share Program (“rTSR Program”)
Performance Period January 1, 2023 - December 31, 2025

IX.    Recoupment Policy

General Recoupment Policy. To the extent permitted by governing law, the Board, in its discretion, may seek Recovery of Performance Share Units granted to a Current Executive Officer or Former Executive Officer if, in the judgment of the Board, such Executive Officer commits misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in capacity as Executive Officer.

Definitions. The following terms shall have the meaning set forth below:

(1) "Current Executive Officer" means any individual currently designated as an “executive officer” by the Board under Rule 3b-7 of the Securities Exchange Act of 1934, as amended.

(2) "Executive Officer" means any Current Executive Officer or Former Executive Officer.

(3) "Former Executive Officer" means any individual previously (but not currently) designated as an “executive officer” by the Board under Rule 3b-7 of the Securities Exchange Act of 1934, as amended.

(4) "Recovery" means the forfeiture or cancellation of unvested Performance Share Units.

Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a "clawback" or alternate recoupment provision to outstanding Performance Share Units, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to the Performance Share Units, as applicable, as if it had been included on the date the Performance Share Units were granted and the Company shall notify the participant of such additional provision.

X.     Other

This document sets forth the terms of the rTSR Program and is not intended to be a contract or             employment agreement between the participant and the Company. As applicable, it is understood that both the participant and the Company have the right to terminate the participant’s employment with the Company at any time, with or without cause and with or without notice, in acknowledgement of the fact that their employment relationship is “at will.”

To the extent section 409A of the Internal Revenue Code (“Code”) applies to any award under this rTSR Program, the award shall be interpreted in a manner consistent with Code section 409A. Where section 409A applies, in the case of any payment made on termination of employment, a termination of employment shall not be deemed to have occurred unless such termination is also a “separation from service” within the meaning of Code section 409A and, for purposes of any such provision, references to a “termination,” “termination of employment,” or like terms shall mean “separation from service.” Where section 409A applies, in the case of a payment made upon a Change in Control, a Change in Control shall not be deemed to have occurred unless there is a change in the ownership or effective control of Boston Scientific, or in the ownership of a substantial portion of the assets of Boston Scientific, as defined in Code section 409A. Where required by section 409A in the case of a specified employee (as determined under Code section 409A), payments on termination shall be made on the first business day of the seventh month following termination.


Boston Scientific Corporation (“Boston Scientific”)
Relative Total Shareholder Return Performance Share Program (“rTSR Program”)
Performance Period January 1, 2023 - December 31, 2025




Boston Scientific Corporation (“Boston Scientific”)
Relative Total Shareholder Return Performance Share Program (“rTSR Program”)
Performance Period January 1, 2023 - December 31, 2025

Appendix A

Annual Executive LTIP Program
S&P 500 Healthcare Index – 64 Companies

Company NameCompany Name
Abbott LaboratoriesHumana Inc
Abbvie IncIDEXX Laboratories
Abiomed IncIllumina Inc
Agilent TechnologiesIncyte Corp
Align TechnologyIntuitive Surg Inc
AmerisourceBergen CorpIQVIA Holdings Inc
Amgen Inc.Johnson & Johnson
Baxter International IncLaboratory Corp of America Holdings
Becton, Dickinson and CompanyMcKesson Corp
Biogen Inc
Medtronic Inc
Bio-Rad LaboratoriesMerck & Company
Bio-Techne CpMettler-Toledo International
Boston Scientific CorpModerna Inc
Bristol-Myers Squibb CompanyMolina Healthcare Inc
Cardinal Health, Inc.Organon & CO
Catalent IncPerkinElmer
Centene CorpPfizer Inc
Charles River Laboratories IntlQuest Diagnostics Inc
Cigna CorporationRegeneron Pharmaceuticals
Cooper CompaniesResMed Inc.
CVS CorpSteris Corp
Danaher CorpStryker Corporation
Davita Healthcare Partners IncTeleflex Inc
Dentsply Sirona IncThermo Fisher Scientific Inc.
Dexcom IncUnitedHealth Group Inc
Edwards Lifesciences CorpUniversal Health Services
Elevance Health IncVertex Pharmaceuticals
Eli Lilly and CompanyViatris Inc.
Gilead Sciences IncWaters Corporation
HCA Holdings IncWest Pharmaceutical Services
Henry Schein IncZimmer Biomet Holdings
Hologic, Inc.Zoetis Inc

EX-10.3 4 exhibit103bostonscientific.htm EX-10.3 Document
Boston Scientific Corporation (“Boston Scientific”)
Organic Net Sales Growth Performance Share Program
(“ONSG Program”)
Performance Period January 1, 2023 - December 31, 2025

I.    Purpose of the ONSG Program

The purpose of the ONSG Program is to align Boston Scientific’s executive compensation program with the interests of shareholders and to reinforce the concept of pay for performance by providing incentives for the achievement of key business performance objectives which are critical to the success of Boston Scientific.

The ONSG Program entails the grant of Restricted Stock Units, and the program shall be administered, under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “2011 LTIP”). Terms not explicitly defined in this ONSG Program document but defined in the 2011 LTIP shall have the same meaning as in the 2011 LTIP.
II.    Eligible Participants

The ONSG Program covers members of the Executive Committee on the date that awards are granted under the ONSG Program as determined and in the amounts established by the Executive Compensation and Human Resources Committee of the Board of Directors (the “Committee”).

III.    Performance Share Units

The Restricted Stock Units awarded under the ONSG Program (the “Performance Share Units”) shall vest only upon satisfaction of both the performance criteria described in this Section III and the payment eligibility criteria described in Section V.

The performance criteria are based on Boston Scientific’s achievement of the 2023 - 2025 financial plan performance for Organic Net Sales Growth. Organic Net Sales Growth will be measured over a three-year performance period beginning January 1, 2023 and ending on December 31, 2025.

The number of Performance Share Units as to which the performance criteria under this ONSG Program shall be determined to have been satisfied will be in a range of 0% to 200% of the target number of Performance Share Units awarded to the participant.

Following the end of the Performance Period, the Committee shall determine the number of Performance Share Units as to which the performance criteria of this ONSG Program have been satisfied, which determination shall be final and binding. Shares of Common Stock will be delivered or otherwise made available to the participant no later than March 15, 2026 in settlement of the Performance Share Units as to which the performance criteria of this ONSG Program have been satisfied if and to the extent the payment eligibility criteria of Section V below are also satisfied. Any Performance Share Units as to which the performance criteria of this Section III have not been satisfied shall be forfeited in their entirety.

IV.    Definitions

“Full month” means 16 or more days.

“Organic Net Sales Growth (ONSG)” excludes from reported net sales the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.

“Partial month” means less than 16 days.



Boston Scientific Corporation (“Boston Scientific”)
Organic Net Sales Growth Performance Share Program
(“ONSG Program”)
Performance Period January 1, 2023 - December 31, 2025

“Performance Period” means the one-year period commencing January 1, 2023 and ending on December 31, 2025.

V.    Payment Eligibility Criteria

Except as set forth below with respect to a Change in Control, no Performance Share Units shall vest prior to the end of the Performance Period (December 31, 2025).

If a participant’s employment with Boston Scientific and its Affiliates (the “Company”) terminates before the last day of the Performance Period, all of his or her Performance Share Units shall be forfeited in their entirety except as set forth below.

Participants on military, sick or other bona fide leave of absence on December 31, 2025 will not be deemed to have terminated employment with the Company if such absence does not exceed 180 days or, if longer, the period the participant retains the right by statute or by contract to return to employment with the Company.

Subject to the terms of any separate Change in Control or similar agreement to which a participant is bound, if there is a Change in Control after December 31, 2023 but before the end of the Performance Period, shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this ONSG Program have been satisfied using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2025, as determined by the Committee immediately prior to the consummation of the Change in Control. Such issuance shall occur within 70 days of the effective date of the Change in Control on a prorated basis. The number of shares to be issued on a prorated basis shall be determined as follows: (# Performance Share Units achieved pursuant to the table in Section III * ((# of full and partial months during the Performance Period, rounded up to the nearest whole month/36)). The number of prorated shares to be issued to the participant, if any, will be approved by the Committee at its next regular meeting. In the event a Change in Control occurs prior to January 1, 2023, the Performance Share Units will be forfeited in their entirety.

If a participant’s employment with the Company terminates due to Retirement after December 31, 2023 but before the end of the Performance Period, the participant will continue to be eligible to vest in a prorated number of Performance Share Units and shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this ONSG Program have been satisfied at the end of the Performance Period, but no later than March 15, 2026, on a prorated basis using the effective date of the participant’s termination of employment. The number of shares to be issued on a prorated basis shall be determined as follows: (# Performance Share Units achieved pursuant to the table in Section III * ((# of full and partial months worked during the Performance Period, rounded up to nearest whole month) / 36)). The number of prorated shares, if any, to be issued to the participant will be approved by the Committee at its regular meeting next following the date of the participant’s employment termination.

If a participant’s employment with the Company terminates due to death or Disability before the end of the Performance Period, the participant will continue to be eligible to vest in all of his or her Performance Share Units and shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this ONSG Program have been satisfied at the end of the Performance Period, but no later than March 15, 2026. The number of shares, if any, to be issued to the participant will be approved by the Committee at its regular meeting next following the date of the participant’s employment termination.



Boston Scientific Corporation (“Boston Scientific”)
Organic Net Sales Growth Performance Share Program
(“ONSG Program”)
Performance Period January 1, 2023 - December 31, 2025

VI.    Termination, Suspension or Modification and Interpretation of the ONSG Program

The Committee has sole authority over administration and interpretation of the ONSG Program. The Committee hopes and expects to continue the ONSG Program in effect but retains its right to exercise discretion as it sees fit, terminate, suspend or modify the ONSG Program or criteria for eligible participation in future years. If suspended, the Committee may reinstate with or without modification all or part of the ONSG Program or criteria for eligible participation. However, no amendment of the ONSG Program after the grant date may materially and adversely impair a participant’s rights under awards made pursuant to the ONSG Program without the participant’s consent unless the amendment is necessary or desirable to facilitate compliance with applicable law, as determined in the sole discretion of the Committee. The Committee reserves the exclusive right to determine eligibility to participate in this ONSG Program and to interpret all applicable terms and conditions.

VII.    Recoupment Policy

General Recoupment Policy. To the extent permitted by governing law, the Board, in its discretion, may seek Recovery of Performance Share Units granted to a Current Executive Officer or Former Executive Officer if, in the judgment of the Board, such Executive Officer commits misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in capacity as Executive Officer.

Definitions. The following terms shall have the meaning set forth below:

(1)    "Current Executive Officer" means any individual currently designated as an “executive officer” by the Board under Rule 3b-7 of the Securities Exchange Act of 1934, as amended.

(2)    "Executive Officer" means any Current Executive Officer or Former Executive Officer.

(3)    "Former Executive Officer" means any individual previously (but not currently) designated as an “executive officer” by the Board under Rule 3b-7 of the Securities Exchange Act of 1934, as amended.

(4) "Recovery" means the forfeiture or cancellation of unvested Performance Share Units.

Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a "clawback" or alternate recoupment provision to outstanding Performance Share Units, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to the Performance Share Units, as applicable, as if it had been included on the date the Performance Share Units were granted and the Company shall notify the participant of such additional provision.

VIII.    Other

This document sets forth the terms of the ONSG Program and is not intended to be a contract or employment agreement between the participant and the Company. As applicable, it is understood that both the participant and the Company have the right to terminate the participant’s employment with the Company at any time, with or without cause and with or without notice, in acknowledgement of the fact that their employment relationship is “at will.”

To the extent section 409A of the Internal Revenue Code (“Code”) applies to any award under this ONSG Program, the award shall be interpreted in a manner consistent with Code section 409A.


Boston Scientific Corporation (“Boston Scientific”)
Organic Net Sales Growth Performance Share Program
(“ONSG Program”)
Performance Period January 1, 2023 - December 31, 2025

Where section 409A applies, in the case of any payment made on termination of employment, a termination of employment shall not be deemed to have occurred unless such termination is also a “separation from service” within the meaning of Code section 409A and, for purposes of any such provision, references to a “termination,” “termination of employment,” or like terms shall mean “separation from service.” Where section 409A applies, in the case of a payment made upon a Change in Control, a Change in Control shall not be deemed to have occurred unless there is a change in the ownership or effective control of Boston Scientific, or in the ownership of a substantial portion of the assets of Boston Scientific, as defined in Code section 409A. Where required by section 409A in the case of a specified employee (as determined under Code section 409A), payments on termination shall be made on the first business day of the seventh month following termination.

EX-101.SCH 5 bsx-20221118.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Document link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 6 bsx-20221118_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 7 bsx-20221118_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 5.50% MCPS, Series A [Member] 5.50% MCPS, Series A [Member] 5.50% MCPS, Series A Entity Central Index Key Entity Central Index Key Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Soliciting Material Soliciting Material Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Class of Stock [Domain] Class of Stock [Domain] City Area Code City Area Code Entities [Table] Entities [Table] Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Senior Note due 2027 [Member] Senior Note due 2027 [Member] Senior Note due 2027 [Member] Entity Information [Line Items] Entity Information [Line Items] Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Tax Identification Number Entity Tax Identification Number Common Stock [Member] Common Stock [Member] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, City or Town Entity Address, City or Town Class of Stock [Axis] Class of Stock [Axis] Local Phone Number Local Phone Number Written Communications Written Communications Cover page. Cover [Abstract] Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 8 bsx-20221118_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 9 logo2021compensationplans.jpg begin 644 logo2021compensationplans.jpg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percentileperformancecalcu.jpg begin 644 percentileperformancecalcu.jpg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end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Document
Nov. 18, 2022
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Nov. 18, 2022
Entity Registrant Name BOSTON SCIENTIFIC CORPORATION
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 1-11083
Entity Tax Identification Number 04-2695240
Entity Address, Address Line One 300 Boston Scientific Way
Entity Address, City or Town Marlborough
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01752-1234
City Area Code 508
Local Phone Number 683-4000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000885725
Common Stock [Member]  
Entity Information [Line Items]  
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol BSX
Security Exchange Name NYSE
Senior Note due 2027 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 0.625% Senior Notes due 2027
Trading Symbol BSX27
Security Exchange Name NYSE
5.50% MCPS, Series A [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share
Trading Symbol BSX PR A
Security Exchange Name NYSE
XML 12 bsx-20221118_htm.xml IDEA: XBRL DOCUMENT 0000885725 2022-11-18 2022-11-18 0000885725 us-gaap:CommonStockMember 2022-11-18 2022-11-18 0000885725 bsx:SeniorNotedue2027Member 2022-11-18 2022-11-18 0000885725 bsx:A550MCPSSeriesAMember 2022-11-18 2022-11-18 0000885725 false 8-K 2022-11-18 BOSTON SCIENTIFIC CORPORATION DE 1-11083 04-2695240 300 Boston Scientific Way Marlborough MA 01752-1234 508 683-4000 false false false false Common Stock, $0.01 par value per share BSX NYSE 0.625% Senior Notes due 2027 BSX27 NYSE 5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share BSX PR A NYSE false EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 4 22 1 false 3 0 false 0 false false R1.htm 0000001 - Document - Cover Document Sheet http://www.bostonscientific.com/role/CoverDocument Cover Document Cover 1 false false All Reports Book All Reports bsx-20221118.htm bsx-20221118.xsd bsx-20221118_def.xml bsx-20221118_lab.xml bsx-20221118_pre.xml exhibit101bostonscientific.htm exhibit102bostonscientific.htm exhibit103bostonscientific.htm http://xbrl.sec.gov/dei/2022 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bsx-20221118.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "bsx-20221118_def.xml" ] }, "inline": { "local": [ "bsx-20221118.htm" ] }, "labelLink": { "local": [ "bsx-20221118_lab.xml" ] }, "presentationLink": { "local": [ "bsx-20221118_pre.xml" ] }, "schema": { "local": [ "bsx-20221118.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 2, "memberStandard": 1, "nsprefix": "bsx", "nsuri": "http://www.bostonscientific.com/20221118", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bsx-20221118.htm", "contextRef": "i4720d8bcab8946bf884d02b23cba50b7_D20221118-20221118", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Document", "role": "http://www.bostonscientific.com/role/CoverDocument", "shortName": "Cover Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bsx-20221118.htm", "contextRef": "i4720d8bcab8946bf884d02b23cba50b7_D20221118-20221118", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "bsx_A550MCPSSeriesAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.50% MCPS, Series A", "label": "5.50% MCPS, Series A [Member]", "terseLabel": "5.50% MCPS, Series A [Member]" } } }, "localname": "A550MCPSSeriesAMember", "nsuri": "http://www.bostonscientific.com/20221118", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "domainItemType" }, "bsx_SeniorNotedue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Note due 2027 [Member]", "label": "Senior Note due 2027 [Member]", "terseLabel": "Senior Note due 2027 [Member]" } } }, "localname": "SeniorNotedue2027Member", "nsuri": "http://www.bostonscientific.com/20221118", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 19 0000885725-22-000030-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000885725-22-000030-xbrl.zip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